Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 8, 2010, Pages 755-762

  Liu, Jing ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anaplastic thyroid carcinoma; Cancer stem cell; Epithelial mesenchymal transition; Follicular thyroid carcinoma; Immunohistochemistry; Papillary thyroid carcinoma

Indexed keywords

CADHERIN; CD133 ANTIGEN; CD44 PROTEIN, HUMAN; GLYCOPROTEIN; HERMES ANTIGEN; INTERMEDIATE FILAMENT PROTEIN; LEUKOCYTE ANTIGEN; NERVE PROTEIN; NESTIN; PEPTIDE; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; THYROID TUMOR; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ANTIGENS, CD; ANTIGENS, CD44; CADHERINS; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PEPTIDES; PHENOTYPE; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952775122     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Ordonez N, Baloch Z, Matias-Guiu X, Evans H, Farid NR, Fagin JA, Kitamura Y, Tallini G, Eng C, Haigh PI, Faquin WC, Sugitani I, Giuffrida D and Boerner S: Undifferentiated (anaplastic) carcinoma. WHO classification of tumors - pathology and genetics of tumours of endocrine organs. Edited by DeLellis RA, Lloyd RV, Heitz PU and Eng C. Lyon, France, IARC press, 2004, pp. 77-80.
2. Tennvall J, Lundell G, Wahlberg P, Bergenfelz, Brimelius L, Akerman M, Skog A-LH and Wallin G. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002;86:1848-1853.
3. McIver B, hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA and Goellner JR. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 2001;130:1028-34.
4. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H and Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321-330.
5. Nishiyama RH, Dunn EL and Thompson NW. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 1972;30:113-127.
6. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, Simpson K, Angeles A and Henson DE. Histologic variant of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroidglobulin inclusions. Am J Surg Pathol 2007;31:729-736.
7. Carcangiu ML, Steeper T, Zampi G and Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 1985;83:135-158.
8. Thiery JP and Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142.
9. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990;59:237-252.
10. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-357.
11. Kang Y and Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-279.
12. Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, Miyauchi A, Okayama A and Tamura K. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol 2006;125:399-406.
13. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D and Gilks B. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 2006;191:581-587.
14. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A and Jones SJ. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007;142:717-729.
15. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ and Guan XY. Identification and characterization of tumorigenic liver cancer stem/ progenitor cells. Gastroenterology 2007;132:2542-2556.
16. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
17. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009;133:568-579.
18. Huntly BJ and Gilliland DG. Leukemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005;5:311-321.
19. Vescovi AL, Galli R and Reynolds BA. Brain tumor stem cells. Nat Rev Cancer 2006;6:425-436.
20. McDermott SP and Wicha MS. Targeting breast cancer stem cells. Mol Oncol 2010 Jun 17. [Epub ahead of print].
21. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V and Yamashita S. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007;148:1797-1803.
22. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A and Giordano C. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 2008;3:e3544. Epub 2008 Oct 28.
23. Friedman S, Lu M, Schultz A, Thomas D and Lin RY. CD133+ anaplastic thyroid cancer cells initiated tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 2009;4 (4):e5395. Epub 2009 Apr 30.
24. Yamada H, Takano T and Ito Y. Expression of nestin mRNA in a differentiation marker in thyroid tumors. Cancer Lett 2009;280:61-64.
25. Caillou B, Malouf G. Anaplastic cancer of the thyroid: an example of epithelial-mesenchymal transition. Ann Pathol 2009;29:S67-S68.
26. Guarino M. Eithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 2007;39:2153-2160.
27. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715.
28. Morel A-P, Lievre M, Thomas C, Hinkal G, Ansieau S and Puisieux A. Generation of breast cancer stem cells through epithelialmesenchymal transition. PLoS One 2008;3:1-7.
29. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S and Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009;69:2887-2895.
30. Ahmed N, Abubaker K, Findlay J and Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010;10:268-278.
31. Du Z, Qin R, Wei C, Wang M, Shi C, Tian R, Peng C. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci 2010;Aug 4. [Epub ahead of print]
32. Giannoni E, Bianchini F, Masieri L, Semi S, Torre E, Calorini L, Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010 Aug 10. [Epub ahead of print]
33. Fuxe J, Vincent, de Herreros AG. Transcriptional crosstalk between TGFbeta and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle 2010;9:2363-2374.
34. Olmeda D, Moreno-Bueno G, Sarrio D, Palacios J, Cano A: Invasion program of normal and cancer stem cells. Cancer stem cells, identification and targets. Edited by Bapat S. New Jersey, John Wiley & Sons, Inc, 2009. pp. 177-178.
35. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMTactivator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRMAs. Nat Cell Biol 2009;11:1487-1495.
36. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J and Terzis AJ. Opinion: The origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005;5:899-904.
37. Tohyama T, Lee VM, Rorke LB, Marvin M, Mckay RD and Trojanowski JQ. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest 1992;66:303-313.
38. Mokry J, Cizkova D, Filip S, Ehrmann J, Osterreicher J, Kolar Z and English D. Nestin expression by newly formed human blood vessels. Stem Cells Dev 2004;13:658-664.
39. Gallo R, Gambelli F, Gava B, Sasdelli F, Tellone V, Masini M, Marchetti P, Dotta F and Sorrentino V. Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death Differ 2007;14:1860-1871.
40. Liu C, Chen B, Zhu J, Zhang R, Yao F, Jin F, Xu H and Lu P. Clinical implications for nestin protein expression in breast cancer. Cancer Sci 2010;101:815-819.
41. Sellheyer K, Nelson P, Krahl D. Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells? Br. J. Dematol 2009;16:1317-1322.
42. Kobayashi M, Sjoberg G, Soderhall S, Lendahl U, Sandstedt B, Sejersen T. Pediatric rhabdomyosarcomas express the intermediate filament nestin. Pediatr Res 1998;43:386-392.
43. Murphy AJ, Viero S, Ho M, Thomer PS. Diagnostic utility of nestin expression in pediatric tumors in the region of the kidney. Appl Immunohistochem Mol Morphol 2009;17:517-523.
44. Teranishi N, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Seya T, Shinji S and Tajiri T. Identification of neovasculature using nestin in colorectal cancer. Int J Oncol 2007;30:593-603.
45. Ehrmann J, Kolar Z and Mokry J. Nestin as a diagnostic and prognostic marker: Immunohistochemical analysis of its expression in different tumour. J Clin Pathol 2005;58:222-223.
46. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM. Cancer stem cells - perspectives in current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
47. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R and Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010;23:450-457.
48. Tong Q-S, Zheng L-D, Tang S-T, Ruan Q-L, Liu Y, Li S-W, Jiang G-S and Cai J-B. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 2008;4:58-62.
49. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber H-P, Van Orden KL, Moore PA, Ruben SM and Carter PJ. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-109.
50. Zenali MJ, Tan D, Li W, Dhingra S and Brown RE. Stemness characteristics of fibrolamellar hepatocelular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. Ann Clin Lab Sci 2010;40:126-134.
51. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S and Scambia G. CD133 antigen expression in ovarian cancer. BMC Cancer 2009;9:221.
52. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F and Dou K Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008;62:1212-1218.
53. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y and Chen Q. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751-6760.
54. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:10153-10163.
55. Pries R, Witrkopf N, Trenkle T, Nitsch SM and Wollenberg B. Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. In Vivo 2008;22:89-92.
56. Braun J, Hoang-Vu C, Dralle H, Huttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinoma. Oncogene 2010;29:4237-4244.